EWTX - NASDAQ
Edgewise Therapeutics, Inc.
$36.21
-1.7%Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
At a Glance
Live Snapshotewtx
Research Development Expenses
Last Annual Value
151.39M
3-Year CAGR
41%
5-Year CAGR
59%
10-Year CAGR
33%
Edgewise Therapeutics, Inc. Competitors Analysis of research-development-expenses
| Company | research-development-expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Edgewise Therapeutics, Inc. NASDAQ:EWTX | 151.39M | 18.5% | 36.3% | N/A | |
 uniQure N.V. NASDAQ:QURE | 140.67M | -13.2% | -0.4% | 6.9% | |
 Vera Therapeutics, Inc. NASDAQ:VERA | 215.26M | 40.1% | 57.1% | N/A | |
 Structure Therapeutics Inc. NASDAQ:GPCR | 225.25M | 47.6% | 50.6% | N/A | |
 Viridian Therapeutics, Inc. NASDAQ:VRDN | 338.93M | 28.5% | 42.9% | 81.2% | |
 Nuvation Bio Inc. NYSE:NUVB | 115.11M | 17.3% | 10.8% | N/A | |
 Celldex Therapeutics, Inc. NASDAQ:CLDX | 245.10M | 27.6% | 34.0% | 9.1% | |
 Janux Therapeutics, Inc. NASDAQ:JANX | 125.90M | 31.9% | 36.8% | N/A | |
 Ocular Therapeutix, Inc. NASDAQ:OCUL | 197.10M | 47.8% | 31.5% | 22.0% |
Edgewise Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your EWTX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.